Desmopressin stimulates vWF release from endothelial cells, which promotes the stabilization of the residual factor VIII.

去氨加压素刺激血管性血友病因子vWF从内皮细胞释放，这能增强剩余因子VIII的稳定性。

For hemophilia A, desmopressin, also called DDAVP (1-deamino-8-D-arginine vasopressin) is helpful for patients with mild, quantitative factor VIII deficiency.

对于血友病A，去氨加压素（DDAVP）有助于治疗轻症因子VIII数量缺乏。

Treatment of central DI consists of fluid management and drug therapy with the synthetic AVP analogue Desmopressin (DDAVP), that is used as nasal or oral preparation in most cases.

中枢性DI的治疗包括液体管理和合成AVP类似物去氨加压素(DDAVP)的药物治疗，在大多数情况下用作鼻腔或口服制剂。